ION BEAM APPLICATIONS, SA IBA - TRANSPARENCY NOTIFICATION
Louvain-la-Neuve, Belgium, January 25, 2018, 17.35 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on January 23, 2018.
| Reason for the notification | Downwards crossing of the 3% threshold further to the disposal of shares -and thus voting rights- held as loan collateral | |
| Persons subject to the notification requirement | IBA SA, issuer | |
| Persons that dispose of voting rights | Norges Bank | |
| Transaction date | 17/01/2018 | |
| Threshold that is crossed (in %) | 3% Downwards crossing further to the disposal of voting rights | |
| Denominator | 29 962 246 | |
| Voting rights (number) | 859 382 | |
| Voting rights (%) | 2,87% | |
| Chain of control | Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway's foreign exchange reserves and is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for management of the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting as principal and all holdings are registered in the name of Norges Bank. | |
| Additional information | This notification was triggered as a result of a change in share lending and disposal of IBA shares. | |
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
For further information, please contact:
IBA
Stephanie Bauwin
Legal Counsel
+32 10 203 924
Stephanie.bauwin@iba-group.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IBA SA via Globenewswire
